Update in Dermatology
Authors: Rebecca A. Kazin, Nancy R. Lowitt, Mark H. Lowitt
Journal: Annals of Internal Medicine (2001)

Updates17 July 2001Update in DermatologyRebecca A. Kazin, MD, Nancy R. Lowitt, MD, and Mark H. Lowitt, MDRebecca A. Kazin, MDFrom Johns Hopkins University School of Medicine and University of Maryland School of Medicine, Baltimore, Maryland.Search for more papers by this author, Nancy R. Lowitt, MDFrom Johns Hopkins University School of Medicine and University of Maryland School of Medicine, Baltimore, Maryland.Search for more papers by this author, and Mark H. Lowitt, MDFrom Johns Hopkins University School of Medicine and University of Maryland School of Medicine, Baltimore, Maryland.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-2-200107170-00013 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The recent expansion of knowledge about dermatology will substantially affect the practice of internal medicine. The natural histories of several common and important dermatologic diseases have been better elucidated, and a wide spectrum of new therapeutic options has emerged for some of the most vexing diseases. We highlight and discuss 10 articles from the past 2 years that illustrate progress in dermatologic areas of interest to the internist.As the number of patients infected with the hepatitis C virus (HCV) continues to increase, early diagnosis remains paramount. Recent investigations suggest that two cutaneous diseases, lichen planus (1) and porphyria cutanea ...References1. Chuang TY, Stitle L, Brashear R, Lewis C. Hepatitis C virus and lichen planus: a case–control study of 340 patients. J Am Acad Dermatol. 1999;41:787-9. [PMID: 10534648] CrossrefMedlineGoogle Scholar2. Chuang TY, Brashear R, Lewis C. Porphyria cutanea tarda and hepatitis C virus: a case–control study and meta-analysis of the literature. J Am Acad Dermatol. 1999;41:31-6. [PMID: 10411407] CrossrefMedlineGoogle Scholar3. Kanazawa K, Yaoita H, Tsuda F, Okamoto H. Hepatitis C virus infection in patients with urticaria. J Am Acad Dermatol. 1996;35:195-8. [PMID: 8708019] CrossrefMedlineGoogle Scholar4. Smith R, Caul EO, Burton JL. Urticaria and hepatitis C [Letter]. Br J Dermatol. 1997;136:980. [PMID: 9217850] CrossrefMedlineGoogle Scholar5. Doutre MS, Beylot-Barry M, Beylot C. Urticaria and hepatitis C infection [Letter]. Br J Dermatol. 1998;138:194-5. [PMID: 9536251] CrossrefMedlineGoogle Scholar6. Llanos F, Raison-Peyron N, Meunier L, Ducos J, Meynadier J. Hepatitis C virus infection in patients with urticaria [Letter]. J Am Acad Dermatol. 1998;38:646. [PMID: 9555818] CrossrefMedlineGoogle Scholar7. Nahmias AJ, Lee FK, Beckman-Nahmias S. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl. 1990;69:19-36. [PMID: 2175939] MedlineGoogle Scholar8. Schomogyi M, Wald A, Corey L. Herpes simplex virus-2 infection. An emerging disease? Infect Dis Clin North Am. 1998;12:47-61. [PMID: 9494829] CrossrefMedlineGoogle Scholar9. Cowan FM, Johnson AM, Ashley R, Corey L, Mindel A. Relationship between antibodies to herpes simplex virus (HSV) and symptoms of HSV infection. J Infect Dis. 1996;174:470-5. [PMID: 8769602] CrossrefMedlineGoogle Scholar10. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis. 1998;26:541-53. [PMID: 9524821] CrossrefMedlineGoogle Scholar11. Reusser P. Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options. J Hosp Infect. 1996;33:235-48. [PMID: 8864937] CrossrefMedlineGoogle Scholar12. Schindl A, Neumann R. Low-intensity laser therapy is an effective treatment for recurrent herpes simplex infection. Results from a randomized double-blind placebo-controlled study. J Invest Dermatol. 1999;113:221-3. [PMID: 10469307] CrossrefMedlineGoogle Scholar13. Al-Watban F, Zhang X. Comparison of the effects of laser therapy on wound healing using different laser wavelengths. Laser Therapy. 1996;8:127-35. CrossrefGoogle Scholar14. Yu HS, Chang KL, Yu CL, Chen JW, Chen GS. Low-energy helium-neon laser irradiation stimulates interleukin-1 α and interleukin-8 release from cultured human keratinocytes. J Invest Dermatol. 1996;107:593-6. [PMID: 8823366] CrossrefMedlineGoogle Scholar15. Drake LA, Ceilley RI, Cornelison RL, Dobes WA, Dorner W, Goltz RW, et al . Guidelines of care for basal cell carcinoma. The American Academy of Dermatology Committee on Guidelines of Care. J Am Acad Dermatol. 1992;26:117-20. [PMID: 1732317] CrossrefMedlineGoogle Scholar16. Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med. 1992;327:1649-62. [PMID: 1435901] CrossrefMedlineGoogle Scholar17. Laihia JK, Uksila J, Luhtala M, Jansén CT. Expression of CD80 (B7/BB-1) and CD28 in human white blood cells treated with urocanic acid. Arch Dermatol Res. 1996;288:570-4. [PMID: 8919038] CrossrefMedlineGoogle Scholar18. Cornell RC, Greenway HT, Tucker SB, Edwards L, Ashworth S, Vance JC, et al . Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol. 1990;23:694-700. [PMID: 2229497] CrossrefMedlineGoogle Scholar19. Imbertson LM, Beaurline JM, Couture AM, Gibson SJ, Smith RM, Miller RL, et al . Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol. 1998;110:734-9. [PMID: 9579537] CrossrefMedlineGoogle Scholar20. Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, et al . Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol. 1998;134:25-30. [PMID: 9449906] CrossrefMedlineGoogle Scholar21. Chouela EN, Abeldaño AM, Pellerano G, La Forgia M, Papale RM, Garsd A, et al . Equivalent therapeutic efficacy and safety of ivermectin and lindane in the treatment of human scabies. Arch Dermatol. 1999;135:651-5. [PMID: 10376691] CrossrefMedlineGoogle Scholar22. Meinking TL, Taplin D. Advances in pediculosis, scabies, and other mite infestations. Adv Dermatol. 1990;5:131-50. [PMID: 2204369] MedlineGoogle Scholar23. Glaziou P, Cartel JL, Alzieu P, Briot C, Moulia-Pelat JP, Martin PM. Comparison of ivermectin and benzyl benzoate for treatment of scabies. Trop Med Parasitol. 1993;44:331-2. [PMID: 8134777] MedlineGoogle Scholar24. Marty P, Gari-Toussaint M, Le Fichoux Y, Gaxotte P. Efficacy of ivermectin in the treatment of an epidemic of sarcoptic scabies. Ann Trop Med Parasitol. 1994;88:453. [PMID: 7979634] CrossrefMedlineGoogle Scholar25. Meinking TL, Taplin D, Hermida JL, Pardo R, Kerdel FA. The treatment of scabies with ivermectin. N Engl J Med. 1995;333:26-30. [PMID: 7776990] CrossrefMedlineGoogle Scholar26. Cordoliani F, Vasseur E, Baccard M, Fournier S, Feuilhade de Chauvin M, Tancrede E, et al . Ivermectin-responsive crusted scabies in HTLV1 carrier. Dermatology. 1996;192:351-2. [PMID: 8864373] CrossrefMedlineGoogle Scholar27. del Giudice P, Marty P, Gari-Toussaint M, Le Fichoux Y. Ivermectin in elderly patients [Letter]. Arch Dermatol. 1999;135:351-2. [PMID: 10086466] CrossrefMedlineGoogle Scholar28. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5 α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974;186:1213-5. [PMID: 4432067] CrossrefMedlineGoogle Scholar29. Dallob AL, Sadick NS, Unger W, Lipert S, Geissler LA, Gregoire SL, et al . The effect of finasteride, a 5 α-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab. 1994;79:703-6. [PMID: 8077349] MedlineGoogle Scholar30. Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, et al . Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998;39:578-89. [PMID: 9777765] CrossrefMedlineGoogle Scholar31. Munro DD, Verbov JL, O'Gorman DJ, du Vivier A. Axillary hyperhidrosis. Its quantification and surgical treatment. Br J Dermatol. 1974;90:325-9. [PMID: 4823088] CrossrefMedlineGoogle Scholar32. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 1986;2:245-7. [PMID: 2874278] CrossrefMedlineGoogle Scholar33. Böni R, Kreyden OP, Burg G. Revival of the use of botulinum toxin: application in dermatology. Dermatology. 2000;200:287-91. [PMID: 10894957] CrossrefMedlineGoogle Scholar34. Schnider P, Binder M, Auff E, Kittler H, Berger T, Wolff K. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol. 1997;136:548-52. [PMID: 9155956] CrossrefMedlineGoogle Scholar35. Hoppe RT, Wood GS, Abel EA. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment. Curr Probl Cancer. 1990;14:293-371. [PMID: 2245651] CrossrefMedlineGoogle Scholar36. Bunn PA2, Lamberg SI. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep. 1979;63:725-8. [PMID: 445521] MedlineGoogle Scholar37. Kim YH, Bishop K, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol. 1995;131:1003-8. [PMID: 7661601] CrossrefMedlineGoogle Scholar38. Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol. 1996;132:1309-13. [PMID: 8915308] CrossrefMedlineGoogle Scholar39. Kim YH, Chow S, Varghese A, Hoppe RT. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol. 1999;135:26-32. [PMID: 9923777] CrossrefMedlineGoogle Scholar40. Grundmann-Kollmann M, Korting HC, Behrens S, Kaskel P, Leiter U, Krähn G, et al . Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol. 1999;40:957-60. [PMID: 10365927] CrossrefMedlineGoogle Scholar41. Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos JD, et al . A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med. 1997;337:816-21. [PMID: 9295241] CrossrefMedlineGoogle Scholar42. Cooper KD. Atopic dermatitis: recent trends in pathogenesis and therapy. J Invest Dermatol. 1994;102:128-37. [PMID: 8288906] CrossrefMedlineGoogle Scholar43. Ruzicka T, Ring J, Przybilla B. Handbook of Atopic Eczema. New York: Springer-Verlag; 1991. Google Scholar44. Grewe M, Gyufko K, Schöpf E, Krutmann J. Lesional expression of interferon-γ in atopic eczema. Lancet. 1994;343:25-6. [PMID: 7905045] CrossrefMedlineGoogle Scholar45. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13:136-42. [PMID: 1374612] CrossrefMedlineGoogle Scholar46. Lauerma AI, Maibach HI, Granlund H, Erkko P, Kartamaa M, Stubb S. Inhibition of contact allergy reactions by topical FK506 [Letter]. Lancet. 1992;340:556. [PMID: 1380111] CrossrefMedlineGoogle Scholar47. Nakagawa H, Etoh T, Ishibashi Y, Higaki Y, Kawashima M, Torii H, et al . Tacrolimus ointment for atopic dermatitis [Letter]. Lancet. 1994;344:883. [PMID: 7522297] CrossrefMedlineGoogle Scholar48. Aoyama H, Tabata N, Tanaka M, Uesugi Y, Tagami H. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment [Letter]. Br J Dermatol. 1995;133:494-6. [PMID: 8547017] CrossrefMedlineGoogle Scholar49. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1989;144:13-4. [PMID: 2800895] MedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Johns Hopkins University School of Medicine and University of Maryland School of Medicine, Baltimore, Maryland.Corresponding Author: Mark H. Lowitt, MD, Department of Dermatology, University of Maryland School of Medicine, 405 West Redwood Street, 6th Floor, Baltimore, MD 21201.Current Author Addresses: Dr. Kazin: Department of Medicine, Johns Hopkins University School of Medicine, 1830 East Monument Street, Baltimore, MD 21205.Dr. N. Lowitt: University of Maryland School of Medicine, 655 West Baltimore Street, Room 14-015, Baltimore, MD 21201.Dr. M. Lowitt: Department of Dermatology, University of Maryland School of Medicine, 405 West Redwood Street, 6th Floor, Baltimore, MD 21201. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCorrection: Ivermectin Dose in Update in Dermatology Metrics Cited byCorrection: Ivermectin Dose in Update in Dermatology 17 July 2001Volume 135, Issue 2Page: 124-132KeywordsAtopic dermatitisDrugsGenital anatomyHerpes simplexLesionsOintmentsPatientsScabiesToxinsUrticaria ePublished: 17 July 2001 Issue Published: 17 July 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...